Cytek Biosciences Inc. announced preliminary, unaudited revenue results for 2025, estimating total revenue at approximately $201 million. This reflects the company’s ongoing growth, supported by a strong financial profile with about $262 million in cash and marketable securities as of the end of the year. Reagent revenue grew approximately 21% year-over-year in the third quarter of 2025, indicating a significant increase in recurring revenue from reagents and kits. The company’s revenue mix remains diversified across regions and industries, with 50% of revenue from the USA, 26% from EMEA, and 24% from APAC and other regions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytek Biosciences Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.